BidaskClub Upgrades WAVE Life Sciences (WVE) to “Strong-Buy”
WAVE Life Sciences (NASDAQ:WVE) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.
Other research analysts have also issued research reports about the company. Mizuho set a $34.00 price objective on WAVE Life Sciences and gave the stock a “buy” rating in a report on Friday, August 18th. Jefferies Group reissued a “buy” rating and set a $40.00 price objective (down previously from $42.00) on shares of WAVE Life Sciences in a report on Thursday, August 10th. Zacks Investment Research raised WAVE Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday, October 12th. Finally, Leerink Swann reissued an “outperform” rating and set a $53.00 price objective (up previously from $42.00) on shares of WAVE Life Sciences in a report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. WAVE Life Sciences presently has an average rating of “Buy” and an average target price of $41.60.
Shares of WAVE Life Sciences (NASDAQ WVE) traded up $2.15 during midday trading on Friday, hitting $39.35. The stock had a trading volume of 437,935 shares, compared to its average volume of 222,025. WAVE Life Sciences has a 52 week low of $15.15 and a 52 week high of $39.50. The company has a quick ratio of 11.50, a current ratio of 11.50 and a debt-to-equity ratio of 0.01.
In other news, Director Ra Capital Management, Llc bought 423,398 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was bought at an average price of $23.34 per share, for a total transaction of $9,882,109.32. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Chandra Vargeese sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $35.00, for a total value of $52,500.00. The disclosure for this sale can be found here. Insiders own 53.00% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. American International Group Inc. lifted its position in WAVE Life Sciences by 7.1% in the 1st quarter. American International Group Inc. now owns 4,554 shares of the company’s stock worth $125,000 after buying an additional 302 shares during the last quarter. Nationwide Fund Advisors lifted its position in WAVE Life Sciences by 58.1% in the 2nd quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock worth $125,000 after buying an additional 2,470 shares during the last quarter. Wells Fargo & Company MN bought a new stake in WAVE Life Sciences in the 3rd quarter worth approximately $136,000. The Manufacturers Life Insurance Company lifted its position in WAVE Life Sciences by 71.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock worth $175,000 after buying an additional 3,912 shares during the last quarter. Finally, Strs Ohio bought a new stake in WAVE Life Sciences in the 3rd quarter worth approximately $194,000. Institutional investors own 73.74% of the company’s stock.
WAVE Life Sciences Company Profile
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.